

GOVERNMENT OF INDIA  
MINISTRY OF DEFENCE  
DEFENCE RESEARCH & DEVELOPMENT ORGANISATION  
**RAJYA SABHA**  
**UNSTARRED QUESTION NO.2261**  
TO BE ANSWERED ON 9<sup>th</sup> August, 2021

**COVID-19 THERAPY DRUGS DEVELOPED BY DRDO**

2261 SHRI B. LINGAIAH YADAV:

Will the Minister of Defence be pleased to state:

- (a) the details of the COVID-19 therapy drugs, including 2 DG-developed by the Defence Research and Development Organisation (DRDO); and
- (b) the manner in which it was useful to the patients?

**ANSWER**  
MINISTER OF STATE IN THE MINISTRY OF DEFENCE  
SHRI AJAY BHATT

(a) An anti-COVID-19 therapeutic application of the drug 2DG (2-deoxy-D-Glucose) has been developed by DRDO. The effectiveness of 2-DG for controlling SARS-CoV2 virus growth was tested in April, 2020 (alongwith CCMB Hyderabad). Subsequently, clinical trials were conducted (May 2020-May 2021) in collaboration with Dr. Reddy's Laboratories, Hyderabad. Based on results of Phase-II and Phase-III clinical trials, DCGI has granted permission for Emergency use of 2DG as adjunct therapy in moderate to severe COVID-19 patients under Hospital setting. The drug comes in powder form in sachet, which is taken orally by dissolving it in water.

(b) 2-DG is an anti-viral and anti-inflammatory drug. It accumulates in the virus infected cells and prevents virus growth by reducing energy production. Clinical trial results have shown faster recovery of hospitalized patients and reduced dependence on oxygen support.

\*\*\*\*\*